Comprehensive and detailed guide on ‘Osteoarthritis and Weight Loss with GLP-1s: Relieving Your Joints’: sourced medical information, practical recommendations, and expert advice for patients undergoing GLP-1 treatment.
Understanding the Stakes
The topic addressed in this article – osteoarthritis and weight loss with GLP-1s: relieving your joints – is a major concern for patients undergoing treatment with GLP-1 agonists. Recent scientific data, derived from the SURMOUNT and SURPASS clinical trials published in the New England Journal of Medicine and The Lancet, provide factual and nuanced answers. This guide is based on recommendations from HAS, EASO, and SFE.
Obesity has been recognized as a chronic disease by the WHO since 1997. Treatments with GLP-1 agonists (tirzépatide/Mounjaro, sémaglutide/Ozempic/Wegovy) represent a therapeutic revolution that requires comprehensive support: medical follow-up, dietary adjustments, physical activity, and psychological support. Each aspect of the treatment deserves particular attention.
Key Clinical Data
Phase III clinical trials of tirzépatide (SURMOUNT-1 to 4) included over 10,000 participants and demonstrated unprecedented efficacy: an average weight loss of 22.5% at the 15 mg dose after 72 weeks, significant improvement in comorbidities (diabetes, hypertension, dyslipidemia, hepatic steatosis), and an improvement in quality of life measured by validated questionnaires.
Treatment tolerance is generally good. Gastrointestinal side effects (nausea, diarrhea, constipation) are the most frequent but tend to diminish over time with progressive titration. The benefit/risk ratio is considered favorable by the EMA and FDA for authorized indications.
Practical Recommendations
- Consult your doctor regularly (every 1 to 3 months during titration)
- Undergo monitoring blood tests every 3 to 6 months
- Maintain adequate protein intake (minimum 1.2 g/kg/day)
- Engage in regular physical activity (150 min/week according to WHO)
- Document your journey with the MounjaGO app for comprehensive medical reports
- Report any unusual side effects to your healthcare team
Multidisciplinary Support
Obesity treatment is not limited to medication. Specialized obesity centers (CSOs) offer multidisciplinary care including endocrinologists/nutritionists, dietitians, psychologists, physiotherapists, and sometimes surgeons. This comprehensive approach maximizes results and minimizes the risks of complications (deficiencies, sarcopenia, eating disorders).
Track your progress with the MounjaGO app.
FAQ
What are the main recommendations for osteoarthritis under GLP-1 treatment?
Key recommendations include regular medical follow-up, monitoring blood tests, adequate protein intake, and adapted physical activity. Consult your doctor for personalized advice tailored to your situation.
Is tirzépatide (Mounjaro) effective for GLP-1?
The SURMOUNT and SURPASS clinical trials have demonstrated the efficacy of tirzépatide for this indication, with significant documented results. Your doctor will assess the relevance of the treatment for your individual profile.
What side effects should be monitored in relation to osteoarthritis?
Side effects to monitor depend on your personal situation. The most common are gastrointestinal issues (nausea, diarrhea, constipation). Report any unusual symptoms to your doctor for évaluation.
How does the MounjaGO app help with osteoarthritis?
MounjaGO offers comprehensive tracking of injections, weight, side effects, and generates PDF reports for your consultations. This structured tracking improves therapeutic adherence and communication with your doctor.